Patents Examined by Joseph Fischer
  • Patent number: 11197906
    Abstract: The present disclosure relates to, among other things, compositions and methods for treating an inflammatory condition including, but not limited to, ocular inflammation, dry eye disease, and ocular neuropathic pain. One aspect of the present disclosure relates to a composition comprising (a) chemerin or a fragment or analog thereof and (b) a lipid entity linked to the chemerin or fragment or analog thereof.
    Type: Grant
    Filed: January 23, 2017
    Date of Patent: December 14, 2021
    Assignees: On Target Therapeutics LLC, Trustees of Tufts College, Tufts Medical Center
    Inventors: Charles Cohen, Krishna Kumar, Alan S. Kopin, Benjamin N. Harwood, Venkata S. Raman, Pedram Hamrah
  • Patent number: 11174288
    Abstract: Disclosed are peptides comprising an amphiphilic backbone and a cationic heparin-binding motif peptide. The peptides can be used in methods of antimicrobial treatment.
    Type: Grant
    Filed: December 5, 2017
    Date of Patent: November 16, 2021
    Assignee: Northeastern University
    Inventors: Run Chang, Keerthana Subramanian, Mian Wang, Thomas J. Webster
  • Patent number: 11154590
    Abstract: An Nkx3.2 fragment with improved stability under a histopathological environment of arthritis and a pharmaceutical composition containing the Nkx3.2 as an active ingredient are disclosed. The Nkx3.2 fragment has a function to activate NF-?B at the similar level to full-length Nkx3.2 and resistance to proteolysis by Siah1. In addition, the Nkx3.2 fragment exhibited at least a 10-fold improvement in degenerative arthritis treatment effect compared with Nkx3.2 in an animal model-based in vivo efficacy evaluation. Therefore, the Nkx3.2 fragment can be favorably used in the prevention or treatment of arthritis.
    Type: Grant
    Filed: February 28, 2020
    Date of Patent: October 26, 2021
    Assignee: ICM CO., LTD.
    Inventor: Dae-Won Kim
  • Patent number: 11058719
    Abstract: A nutritional supplement composition for treating nutritional deficiencies caused by a medical condition in subjects is disclosed. The present application further discloses a method of using a nutritional supplements composition for treating a subject with complications resulting from sickle cell anemia. The method comprises administering to a subject an effective amount of the nutritional supplement.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: July 13, 2021
    Assignee: MOREHOUSE SCHOOL OF MEDICINE
    Inventors: Jacqueline Hibbert, Jonathan K. Stiles, Kayellen Umeakunne, Hyacinth I. Hyacinth
  • Patent number: 10993988
    Abstract: The present invention relates to a veterinary composition comprising an effective amount of at least one cyclic depsipeptide and at least one macrocyclic lactone; and a pharmaceutically acceptable carrier, for the treatment or prophylaxis of parasitic infection in a mammal wherein the parasite shows resistance to treatment or prophylaxis with the macrocyclic lactone alone.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: May 4, 2021
    Assignee: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.
    Inventors: Brenda Bondesen, Lance Hammerland
  • Patent number: 10987408
    Abstract: A method of promoting hair growth of a subject includes administering to follicle cells of the subject a therapeutically effective amount of a TLR2 agonist that promotes TLR2 activation and hair growth of the subject.
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: April 27, 2021
    Assignee: THE CLEVELAND CLINIC FOUNDATION
    Inventor: Tatiana Byzova
  • Patent number: 10968442
    Abstract: Chimeric clotting factors which localize the therapeutic to sites of coagulation (e.g., by being targeted to platelets or being activatable at sites of coagulation), have reduced clearance rates, have improved manufacturability, have reduced thrombogenicity, have enhanced activity, or have more than one of these characteristics are described as are methods for making chimeric clotting factors and methods for improving hemostasis using these clotting factors.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: April 6, 2021
    Assignee: Bioverativ Therapeutics Inc.
    Inventors: Joe Salas, Robert Peters, Alan Bitonti
  • Patent number: 10967000
    Abstract: The present invention relates to a conjugate of cell penetrating peptide and an active ingredient; and its use. Specifically, a conjugate including a cell penetrating peptide which is a peptide comprising amino acid sequence of SEQ ID NO:1, a fragment of any one sequence of SEQ ID NO:1, or a peptide having above 80% homology with the above-mentioned sequence; and a composition comprising the same are disclosed.
    Type: Grant
    Filed: July 11, 2013
    Date of Patent: April 6, 2021
    Assignee: Gemvax & Kael Co., Ltd.
    Inventor: Sang Jae Kim
  • Patent number: 10954287
    Abstract: The present invention provides Ras modulators including inhibitors and/or antagonists of Ras, Ras binding, and Ras-dependent cell signaling activity. Also provided are methods of utilizing the Ras modulators as therapeutics.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: March 23, 2021
    Assignee: RA PHARMACEUTICALS, INC.
    Inventors: Kristopher Josephson, Zhong Ma, Yili Sun, Nathan Ezekiel Nims, Kathleen Seyb, Sylvia Tobe, Ping Ye, Douangsone D. Vadysirisack, Guo-Qing Tang, Douglas A. Treco
  • Patent number: 10786531
    Abstract: The present disclosure generally relates to the medical use of compositions comprising a mineral salt and a sulfonic acid for prevention and/or treatment of one or more mucosal diseases, disorders, or conditions or one or more dermal diseases, disorders, or conditions.
    Type: Grant
    Filed: June 24, 2019
    Date of Patent: September 29, 2020
    Assignee: BMG PHARMA SPA
    Inventors: William A. Goolsbee, Jeffrey L. Lillard
  • Patent number: 10766939
    Abstract: The present invention relates to amylin analogs and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogs have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: September 8, 2020
    Assignee: Zealand Pharma A/S
    Inventors: Rasmus Just, Oliver Demmer, Lise Giehm, Jesper Sloth Villadsen, Henrik Munch, Jesper Mosolff Mathiesen, Jolanta Skarbaliene, Maria Deryabina, Dieter Wolfgang Hamprecht
  • Patent number: 10759839
    Abstract: A cell-penetrating peptide has remarkably excellent cell penetration efficiency, and is capable of penetrating 100% into all cells within 1 hour even in an environment including serum or sera, as well as a stable structure. Therefore, it is possible to move a cargo into the cell while maintaining the function of the cargo without damaging the same.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: September 1, 2020
    Assignee: NEOREGEN BIOTECH
    Inventor: Jeong Min Seo
  • Patent number: 10507227
    Abstract: A method for treating an infection comprises administering a peptide in synergistic combination with an antibiotic, wherein the peptide comprises an amino acid sequence with a formula selected from the group consisting of: Bn1-Z;??(a) Bn1-Z-Bn2; and??(b) Z-Bn1??(c) wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of from about 7 to about 24 amino acid residues, said sequence having an average hydrophobicity value of at least 0.3 on the Liu-Deber scale.
    Type: Grant
    Filed: April 15, 2015
    Date of Patent: December 17, 2019
    Assignee: The Hospital for Sick Children
    Inventor: Charles M. Deber
  • Patent number: 10500165
    Abstract: Purified therapeutic nanoparticles are provided herein. Such nanoparticles comprise an active pharmaceutical ingredient and human serum albumin, wherein the weight ratio of human serum albumin to the active ingredient in the therapeutic nanoparticles is from 0.01:1 to 1:1, and wherein the nanoparticles are substantially free of free human serum albumin that is not incorporated in the nanoparticles. The present disclosure also provides pharmaceutical compositions that comprise the purified therapeutic nanoparticles and are also substantially free of free human serum albumin. Methods for preparing and using the purified therapeutic nanoparticles and compositions thereof are also provided.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: December 10, 2019
    Inventors: Chunlei Li, Yanhui Li, Min Liang, Caixia Wang, Yajuan Wang, Shixia Wang, Dongjian Chen, Yongfeng Li
  • Patent number: 10449257
    Abstract: The present invention relates to composite hydrogels comprising at least one non-peptidic polymer and at least one peptide having the general formula: Z—(X)m—(Y)n—Z?p, wherein Z is an N-terminal protecting group; X is, at each occurrence, independently selected from an aliphatic amino acid, an aliphatic amino acid derivative and a glycine; Y is, at each occurrence, independently selected from a polar amino acid and a polar amino acid derivative; Z? is a C-terminal protecting group; m is an integer selected from 2 to 6; n is selected from 1 or 2; and p is selected from 0 or 1. The present invention further relates to methods of producing the composite hydrogels, to uses of the composite hydrogels for the delivery of drugs and other bioactive agents/moieties, as an implant or injectable agent that facilitates tissue regeneration, and as a topical agent for wound healing.
    Type: Grant
    Filed: November 5, 2012
    Date of Patent: October 22, 2019
    Assignee: Agency for Science, Technology and Research
    Inventors: Charlotte Hauser, Yihua Loo, Andrew C. A. Wan, Michael Reithofer
  • Patent number: 10442847
    Abstract: The present invention relates to glucagon analogs and their medical use, for example in the treatment of hypoglycaemia. In particular, the present invention relates to stable glucagon analogs suitable for use in a liquid formulation.
    Type: Grant
    Filed: July 23, 2013
    Date of Patent: October 15, 2019
    Assignee: Zealand Pharma A/S
    Inventors: Ditte Riber, Lise Giehm
  • Patent number: 10421795
    Abstract: A process is described for purifying insulin and insulin analogs that comprises high-pressure liquid chromatography with an acidic cation exchange medium performed under low to moderate pressure at an elevated temperature.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: September 24, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Michael P. Coleman, Allison D. Ortigosa, Mark C. Sleevi, Kartoa Chow
  • Patent number: 10398750
    Abstract: The present description provides compositions and methods for producing therapeutic oligomeric compounds. In another aspect the description provides methods for administering the oligomeric compounds for the treatment and prevention of disease in a mammal. In particular, the invention relates to medicaments comprising various novel oligomeric compounds and pharmaceutically acceptable salts thereof. The compounds of the invention may optionally be administered with at least one of a pharmaceutically acceptable excipient, additional pharmacologically active agent or a combination thereof.
    Type: Grant
    Filed: August 21, 2014
    Date of Patent: September 3, 2019
    Assignees: UREKA SARL, Centre National De La Recherche Scientifique (CNRS)
    Inventors: Robert H. Zimmer, Gilles Guichard, Juliette Fremaux
  • Patent number: 10351603
    Abstract: Synthetic nanostructures, polypeptides that are useful, for example, in making synthetic nanostructures, and methods for using such synthetic nanostructures are disclosed herein.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: July 16, 2019
    Assignee: University of Washington
    Inventors: David Baker, Jacob B. Bale, Neil P. King, William H. Sheffler, Daniel Ellis
  • Patent number: 10336803
    Abstract: This document provides methods and materials related to insulin secreting polypeptides. For example, polypeptides having the ability to induce insulin secretion and methods and materials for using use such polypeptides to induce insulin secretion and to treat diabetes are provided.
    Type: Grant
    Filed: March 22, 2018
    Date of Patent: July 2, 2019
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Horng H. Chen, John C. Burnett, Jr.